Keeping Up With the Joneses: HCV Retreatment After Failure of a Direct-Acting Antiviral (DAA) Regimen in 2017
Thursday, October 12, 2017
1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)
Assessment of Needs
This webinar will briefly review the potential for the emergence of HCV drug resistance following DAA treatment failure. Dr Wyles will provide historical context for the impact of HCV DAA resistance on retreatment approaches with older DAA regimens. He will also review data supporting the approval of new DAA regimens, focusing on persons whose previous DAA treatment failed. Finally, for such persons, the webinar will offer treatment approaches using newer regimens and taking into account current indications and guideline recommendations.
At the conclusion of this webinar, learners will be able to:
- Describe HCV resistance-associated substitutions after failure of a DAA regimen
- Describe the data supporting the approval of new DAA regimens for the treatment of HCV infection
- Develop a framework for treatment of HCV infection after failure of a DAA regimen, using newly approved treatment regimens
Who Should Attend
This webinar is designed for clinical decision makers, such as physicians, nurse practitioners, and physician assistants, as well as pharmacists who plan to begin treating patients with HCV infection, who have experience in treating HCV infection, and would like to update their knowledge of HCV infection management.
This activity is also relevant for registered nurses, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, October 11, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hour (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-17-264-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.